0.5200 -0.07 (-11.67%)
After hours: 4:30PM EST
|Bid||0.4801 x 1000|
|Ask||0.5500 x 800|
|Day's Range||0.5300 - 0.6733|
|52 Week Range||0.2000 - 7.6900|
|Beta (3Y Monthly)||3.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.50|
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series E Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the proposed offerings may be completed, or as to the actual size or terms of the offerings. Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offerings to fund ongoing development of vecabrutinib, ongoing research and development, debt amortization, and general corporate purposes.
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that the Company has opened the 100 mg cohort in the Phase 1b/2 trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. “Thus far, we have seen an encouraging safety profile, evidence of pharmacodynamic activity in CLL and other B cell cancer patients both with and without BTK C481 mutations, and some improvements in clinical symptoms. Vecabrutinib (SNS-062) is a selective, oral, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results will be presented today, December 2, from 6:00-8:00 p.m. PT in a poster session titled “CLL: Therapy, excluding Transplantation: Poster II” at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. “To date, vecabrutinib has demonstrated both an encouraging safety profile and evidence of pharmacodynamic activity in CLL and other B cell cancer patients both with and without the BTK C481 mutation,” said Dayton Misfeldt, Sunesis interim Chief Executive Officer.
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc. (SNSS) today announced it will provide a program update for vecabrutinib, the Company’s oral, reversible, non-covalent, BTK inhibitor which is currently being evaluated in an ongoing Phase 1b/2 clinical trial in adults with relapsed chronic lymphocytic leukemia (CLL) and other B-cell malignancies. Sunesis’ executive management team will present an update on vecabrutinib from the ongoing Phase 1b/2 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of vecabrutinib in B-lymphoid malignancy patients with prior BTK therapy. The Phase 1b/2 trial is an open-label, sequential-group study that is enrolling patients across eight leading sites in the United States.
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 18 cents. In the final minutes of trading on Monday, the company's shares hit $1.32. A year ago, they were ...
Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported.
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced two poster presentations and an oral presentation at the 60th.
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Monday, November 5th, 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2018. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
A look at the shareholders of Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely,Read More...
The South San Francisco, California-based company said it had a loss of 20 cents per share. In the final minutes of trading on Tuesday, the company's shares hit $2.45. A year ago, they were trading at ...